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Aims: Randomized clinical trials (RCTs) are the most reliable evidence, even if they require important resource
and logistic efforts. Large, cost-free and real-world datasets may be easily accessed yielding to observational
studies, but such analyses often lead to problematic results in the absence of careful methods, especially from a
statistic point of view. We aimed to appraise the performance of current multivariable approaches in the estimation
of causal treatment and effects in studies focusing on drug-eluting stents (DES).
Methods and Results: Pertinent studies published in the literature were searched, selected, abstracted, and
appraised for quality and validity features. Six studies with a logistic regression were included, all of them
reporting more than 10 events for covariates and different length of follow-up, with an overall low risk of bias.
Most of the 15 studies with a Cox proportional hazard analysis had a different follow-up, with less than 10 events
for covariates, yielding an overall low or moderate risk of bias. Sixteen studies with propensity score were included:
the most frequent method for variable selection was logistic regression, with underlying differences in follow-up
and less than 10 events for covariate in most of them. Most frequently, calibration appraisal was not reported
in the studies, on the contrary of discrimination appraisal, which was more frequently performed. In seventeen
studies with propensity and matching, the latter was most commonly performed with a nearest neighbor-matching
algorithm yet without appraisal in most of the studies of calibration or discrimination. Balance was evaluated in
46% of the studies, being obtained for all variables in 48% of them.
Conclusions: Better exploitation and methodological appraisal of multivariable analysis is needed to improve the
clinical and research impact and reliability of nonrandomized studies. (J Interven Cardiol 2012;25:611–621)
Introduction
Randomized clinical trials (RCTs) generate the most
reliable clinical evidence,1 especially when combined
within systematic reviews or meta-analyses. Despite
these strengths, they deserve a critical appraisal2 about
their methodological rigor, to stress their most relevant
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limits like analysis of highly selected patients, subject
attrition, and event adjudication.
Thus, also in interventional cardiology, still a high
number of nonrandomized studies are performed in or-
der to save economical resources,3 to create hypothe-
sis, especially for nonrandomizable patients, or to shed
light on the generalizability of results from existing
randomized experiments.4
In the attempt to exploit the broad potential resources
of observational databases, various statistical models
are currently employed. Several different multivari-
able approaches are available to control for systematic
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Table 1. Statistical Features of Studies with Logistic Regression
Studies N = 6
Time of Publication 2007 (2006–2009)
Study design
– Retrospective 3 (50%)
– Prospective 3 (50%)
Study organization
– One center 3 (50%)
– Multicenter 3 (50%)
Data source
– Clinical database 6 (100%)
Follow-up
Similar 3 (50%)
Nonsimilar 3 (50%)
Censored data
Yes 5 (83%)
No 1 (7%)
Number of events for covariate
Less than 10 0 (100%)
Analytical bias
Low risk 8 (61%)
Moderate risk 5 (39%)
High or unclear risk 0
Selection bias
Low risk 2 (14%)
Moderate risk 4 (86%)
Adjudication bias
Low risk 3 (50%)
Moderate risk 3 (50%)
Attrition bias
Low risk 5 (83%)
Moderate risk 1 (7%)
Overall credibility
Moderate 4 (86%)
High 2 (15%)
baseline differences between groups naturally occur-
ring in the nonrandomized setting.5 Even more their
striking importance lies on defining the impact of sev-
eral independent variables on a single dependent vari-
able, thus avoiding confounding effects coming from
observed variables in nonrandomized studies.
Nevertheless multivariable analysis should be per-
formed according to precise statistical issues,6–12 to
assure accurate and understandable results, and to of-
fer a more pregnant impact on everyday practice.
To our knowledge, no systematic review was per-
formed to assess bulk and quality of multivariable
approaches in observational studies, focusing on the
comparison between drug-eluting stents (DES) versus
bare metal stents (BMS) for percutaneous coronary in-
tervention (PCI). Given this purpose, we explored the
Table 2. Statistical Features of Studies with Cox Proportional
Hazard Analysis
Studies N = 15
Time of Publication 2008 (2008–2009)
Study design
– Retrospective 7 (46%)
– Prospective 8 (54%)
Study organization
– One center 10 (69%)
– Multicenter 5(31%)
Data source
– Clinical database 15 (100%)
Follow-up
Similar 2 (12%)
Nonsimilar 13 (88%)
Censored data
Yes 14 (94%)
No 1 (6%)
Number of events for covariate
Less than 10 10 (60%)
More than 10 4 (24%)
Unclear 1 (6%)
Analytical bias
Low risk 9 (74%)
Moderate risk 6 (36%)
Selection bias
Low risk 8 (48%)
Moderate risk 7 (42%)
Adjudication bias
Low risk 4 (24%)
Moderate risk 8 (48%)
Unclear 3 (18%)
Attrition bias
Low risk 3 (18%)
Moderate risk 9 (54%)
Unclear 3 (18%)
Overall credibility
Moderate 12 (82%)
High 2 (12%)
Very high 1 (6%)
methodological structure of articles, assessed how of-
ten authors explicitly faced the topic of internal valid-
ity, tested the risk for different bias, and, finally, aimed
to propose a score to summarize the overall credibility
of nonrandomized studies
Methods
PubMed was searched for pertinent articles pub-
lished between January 2002 (when DES were
first marketed worldwide) and December 2010 in
keeping with established methods,13 searching for:
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Table 3. Statistical Features of Studies with Propensity Score
Studies N = 16
Time of Publication 2008 (2008–2009)
Study design
Retrospective 5 (32%)
Prospective 11 (68%)
Study organization
One center 10 (63%)
Multicenter 6 (37%)
Data source
Clinical database 14 (84%)
Institutional database 2 (16%)
Follow-up
Similar 2 (12%)
Nonsimilar 14 (84%)
Censored data
Yes 13 (76%)
No 3 (24%)
Number of events for covariate
Less than 10 5 (30%)
More than 10 11 (70%)
Methods to select variables
Logistic regression model 16 (100%)
Variables inserted according to
Nonparsimonious 7 (42%)
Selected variables 11 (68%)
Propensity score included in Cox mul- 5 (30%)
tivariable analysis.
Discrimination appraisal
Not reported 6 (48%)
Reported (median and third quartiles 10 (52%)
of c-index) 0.87 (0.82–0.86)
Calibration appraisal
Not reported 9 (48%)
Reported not significant according to 7 (42%)
Hosmer-Lemeshow test
Collinearity appraisal
Not reported 16 (100%)
Analytical bias
Low risk 10 (64%)
Moderate risk 6 (36%)
Selection bias
Low risk 9 (54%)
Moderate risk 6 (36%)
Unclear 1 (6%)
Adjudication bias
Low risk 7 (42%)
Moderate risk 6 (36%)
Unclear 3 (18%).
Attrition bias
Low risk 3 (18%)
Moderate risk 9 (54%)
Unclear 3 (18%)
Overall credibility
Moderate 12 (82%)
High 2 (12%)
Very high 1 (6%)
• DES and BMS∗ and multivariate analysis
• DES and BMS∗ and multivariable methods
• DES and BMS∗ and logistic regression
• DES and BMS∗ and Cox proportional hazard anal-
ysis
• DES and BMS∗ and propensity score
• DES and BMS∗ and propensity score with
matching
Study Selection. Retrieved citations were first
screened independently by 2 reviewers (G.B.-Z, F.DA.)
at the title and/or abstract level, with divergences re-
solved after consensus. If potentially pertinent, they
were then appraised as complete reports according to
the following explicit selection criteria, which were
piloted over the first 5 cases for consistency and dis-
crimination. Inclusion criteria were (all had to be
met for inclusion): (i) human studies, with nonran-
domized design (ii) investigating patients undergoing
PCI, with implantation of DES and BMS, and (iii)
employing multivariable approaches. Exclusion crite-
ria were (any one alone was enough for exclusion):
(i) nonhuman setting and (ii) RCT design. No di-
mensional cut off in terms of included patients was
used, to offer a wide representation of interventional
studies.
Data Extraction. The following data were ab-
stracted by 2 unblinded independent reviewers (G.B.-
Z, F.DA.) on prespecified forms, which were piloted
over the first 5 cases for consistency and discrimi-
nation, with divergences resolved after consensus. In
particular, authors, journal, year of publication, loca-
tion of the study group were first assessed, and impact
on death, myocardial infarction (MI), repeat revascu-
larization, or their composite, namely major adverse
cardiac events (MACE).
Statistical Methods Appraisal. Studies respond-
ing to inclusion criteria were divided according to
their multivariable approaches12 in logistic regression,
Cox proportional hazard analysis, propensity score and
propensity score with matching. First, for all of these
studies evaluation of difference in follow-up length,
presence of censored data, and number of events per co-
variates was performed. Then, for studies with propen-
sity score adjustment, we analyzed methods for vari-
able selection, prediction, discrimination, calibration
collinearity, and use of parsimonious or not approach.8
Then, if matching was present, matching methods and
balance were also analyzed.
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Table 4. Statistical Features of Studies with Propensity Score with
Matching
Studies N = 17
Time of Publication 2008 (2007–2009)
Study design
Retrospective 7 (45%)
Prospective 10 (55%)
Study organization
One center 12 (75%)
Multicenter 5 (25%)
Data source
Clinical database 15 (79%)
Institutional database 2 (11%)
Follow-up
Similar 2 (11%)
Nonsimilar 15 (79%)
Censored data
Yes 17 (100%)
Number of events for covariate
Less than 10 9 (55%)
More than 10 8 (45%)
Methods to select variables
Logistic regression model 15 (79%)
Unclear 2 (21%)
Variables inserted according to
Nonparsimonious 3 (16%)
Selected variables 13 (64%)
Unclear 1 (5.5%)
Propensity score included in Cox 3 (16%)
multivariable analysis
Matching method
Nearest-neighbor–matching 14 (78%)
algorithm
Quintiles 2 (12%)
Unclear 1 (6%)
Balance assessment
Performed, with differences less than 6 (40%)
10%
Performed, with differences less than 5% 1 (6%)
Unclear 6 (54%)
Balance achieved for
All variables 8(48%)
All except
1 variable 1 (6%)
2 variables 1 (6%)
3 variables 1 (6%)
4 variables 2 (12%)
8 variables 1 (6%)
Nonreported 3 (18%)
Discrimination appraisal
Not reported 11 (63%)
Reported (median and third quartiles 6 (37%)
of c-index)
Calibration appraisal
Not reported 15 (89%)
Reported not significant according to
Hosmer-Lemeshow test
2 (11%)
0.73 (0.71–0.76)
Continued.
Table 4. Continued.
Studies N = 17
Time of Publication 2008 (2007–2009)
Collinearity appraisal
Not reported 14 (78%)
Reported, without reporting high correlation 3 (22%)
Analytical bias
Low risk 13 (78%)
Moderate risk 4 (22%)
Selection bias
Low risk 7 (42%)
Moderate risk 10 (58%)
Adjudication bias
Low risk 7 (42%)
Moderate risk 9 (52%)
Unclear 1 (6%).
Attrition bias
Low risk 5 (30%)
Moderate risk 8 (48%)
Unclear 2 (12%)
Overall credibility
Moderate 9 (54%)
High 6 (36%)
Very high 2 (10%)
Internal Validity and Quality Appraisal. The
quality of included studies was appraised by unblinded
independent reviewers (G.B.-Z, F.DA.), on prespeci-
fied forms, which were piloted over the first 5 cases for
consistency and discrimination, with divergences re-
solved after consensus. Modifying the MOOSE (Meta-
analysis of Observational Studies in Epidemiology)
items to take into account the specific features of in-
cluded studies,4 we separately abstracted and appraised
study design, setting, data source, and statistical meth-
ods for multivariable analysis, as well as risk of ana-
lytical, selection, adjudication, detection, and attrition
bias (expressed as low, moderate, or high risk of bias,
as well as incomplete reporting leading to inability to
ascertain the underlying risk of bias). Moreover, we
appraised the overall credibility of short listed studies,
to summarize the previous features. Zero points were
assigned for retrospective design and single-center set-
ting, 1 for prospective design and for a multicenter
setting. Moreover, 2 points were ascribed for overall
low risk of bias, 1 for moderate risk, and zero for high
or unclear risk. If the sum of these scores was 10, a
very high credibility was granted; if it was between 7
and 9, high; 4 and 6, moderate; 1 and 3, low; 0, very
low (e.g., a multicenter study with prospective design,
with low risk of analytical bias, medium risk of selec-
tion bias, low of attrition bias, medium of adjudication
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bias totally scored 9, thus with high credibility; for fur-
ther details, see Table S1). Moreover, for studies with
propensity score and with propensity score with match-
ing, distribution of statistical features among studies
with moderate and high quality, and among studies in
different quartiles of Impact Factor (IF; CI 95%) was
evaluated.
Data Analysis and Synthesis. Continuous vari-
ables are reported as mean (standard deviation) or me-
dian (range). Categorical variables are expressed as
n/N (%). No formal test of hypothesis was employed
given the exploratory and hypothesis generating scope
of our systematic review.
Results
Fifty-eight studies were initially analyzed: 3 were
excluded for reporting only multivariable analysis
results,14–16 2 because reporting only predictors of
stent thrombosis,17,18 3 because noncomparing directly
BMS and DES19–22; finally 50 studies were included
(Fig. 1).
Six studies with a logistic regression were in-
cluded,23–28 all of them reporting more than 10 events
for covariates and different length of follow-up, with an
overall low risk of bias (Table 1). Logistic regression
did not modify results of univariate analysis. (Fig. 2).
Fifteen studies with a Cox proportional hazard anal-
ysis25,29–42 are described in Table 2. Eighty-eight per-
cent of them had different follow-up, 94% censored
data and 60% reported less than 10 events for covari-
ates. An overall low or moderate risk of bias was ap-
praised. At multivariate analysis, superiority for DES
in reducing myocardial infarction and death was less
frequently reported (Fig. 3).
Sixteen studies with propensity score were ana-
lyzed34,42–56 (Table 3). Logistic regression was always
used for variable selection; 84% of them reported dif-
ferences in follow-up, 70% more than 10 events for
covariate and a nonparsimonious method of variable
selection was noted in 42% of cases. Both calibration
and discrimination appraisal were reported in 52% of
the studies; moreover, propensity score was inserted
in Cox multivariable analysis in 30% of cases. Over-
all analysis showed no differences between BMS and
DES, after multivariable analysis in most cases for
death and myocardial infarction (Fig. 4).
In the 17 included studies,57–73 matching was per-
formed with a nearest neighbor-matching algorithm in
78% of cases (Table 4). Variables were inserted with
a nonparsimonious method in 16% of cases, and bal-
ance was evaluated in 46% of studies, being obtained
for all variables in 48% of them; discrimination was
reported in 37% and calibration in 11% of cases. My-
ocardial infarction and death trended to change, the
former without differences between BMS and DES af-
ter propensity score with matching, the latter showing
a tendency to better outcome after stenting with DES
(Fig. 5).
Interestingly, both after appraisal for IF and qual-
ity differences only small differences were found for
propensity score with matching about discrimination,
calibration, and balance evaluation among different
classes (Figs. 6, 7 and 8). On the contrary, for propen-
sity scores studies within the highest quartiles of IF,
calibration and discrimination were most frequently
reported.
Discussion
The present review originally shows for the first time
that the application of complex multivariable methods
is becoming increasingly popular in nonrandomized
medical research. Yet, statistical analyses of these stud-
ies often lack internal appraisal and validation, a find-
ing approximately independent from the rating of the
journal in which the studies were published. Evaluation
of the methodological quality of such studies through
a synthetic score is feasible and appears important for
a critical approach to medical literature.
Because of great economical and medical policy
changes3 observational studies will gain room in sci-
entific research, and the next era has indeed been de-
fined as the time of comparative-effectiveness research.
RCTs remain the leading evidence; being burdened
from several economical, logistic, and temporal hur-
dles, these costs cannot generate bias-free information
anyway.74−76 Moreover, given the international eco-
nomic scenario and the growing role of conflict of
interest in data interpretation,77,78 researchers ought to
develop new tools to prevent problems affecting the
accuracy and interpretation of results obtained from
widely available observational datasets. As a matter
of fact, such a kind of methodological problem would
make the reported results potentially inaccurate, mis-
leading, or difficult to interpret.
From our review of current literature, multivariable
analysis is the reference method to explore observa-
tional information equally in its different approaches
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279 records idenfied through 
database searching
3 addional citaons obtained
through other sources
58 full texts appraised according to 
explicit  selecon criteria
3 for reporting only multivariate 
analysis report
3 for not directly comparing BMS 
and DES
2 for appraising only stent 
thrombosis as outcome
50 studies finally included in the 
systemac review
Figure 1. Review’s profile.
0 2 4 6 8 10
Bivariate MACE
Mulvariable MACE
Bivariate revascularizaon
Mulvariable revascularizaon
DES beer than BMS no diﬀerence
Figure 2. Performance of logistic regres-
sion studies. (DES = Drug-eluting stent;
BMS = Bare metal stent). Red lines rep-
resented studies reporting first at univariate,
then at multivariate analysis, a significant
better outcome for DES, blue lines for BMS.
0 2 4 6 8 10
Bivariate MACE
Multivariable MACE
Bivariate death
Multivariable death
Bivariate MI
Multivariable MI
Bivariate revascularization
Multivariable revascularization
DES better than BMS no difference
Figure 3. Performance of Cox proportional
hazard analysis studies. Red lines repre-
sented studies reporting first at univariate,
then at multivariate analysis, a significant
better outcome for DES, blue lines for BMS.
(logistic regression, Cox proportional hazard analysis,
propensity score, or propensity score with matching
and multiple logistic regression). All the examined sta-
tistical methods tend to approach observational stud-
ies results to meta-analysis outcomes: actually BMS
did not show, after multivariable approaches, a detri-
mental effect on survival, as demonstrated in 2 recent
systematic reviews.79,80 Thus, to give more statistical
significance to this analysis, it is worthwhile to criti-
cally appraise and develop their internal validity, both
for the point of view of reducing risk of bias and for
the point of view of statistical analysis.8–11 Actually, as
with all scientific models the results require validation
to ensure protection against unrecognized problems
and limitations.
Unfortunately, our results underline an overall mod-
erate risk of adjudication and attrition bias, while the
risk of selection and analytical bias seemed less pro-
nounced. The chance to overcome adjudication- and
attrition-related pitfalls may lie in example in a more
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Bivariate death
Mulvariable death
Bivariate MI
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Bivariate revascularizaon
Mulvariable revascularizaon
DES better than BMS no difference
Figure 4. Performance of propensity score
studies. Red lines represented studies report-
ing first at univariate, then at multivariate anal-
ysis, a significant better outcome for DES,
blue lines for BMS.
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Bivariate MACE
Multivariable MACE
Bivariate death
Multivariable death
Bivariate MI
Multivariable MI
Bivariate revascularization
Multivariable revascularization
DES better than BMS no difference
Figure 5. Performance of propensity score
studies with matching. Red lines represented
studies reporting first at univariate, then at mul-
tivariate analysis, a significant better outcome
for DES, blue lines for BMS.
Discrimination Calibration
4 studies 
in the highest 
IF quartile
4 studies 
in the medium
IF quartile
4 studies 
in the lowest
IF quartile
Not appraised
Appraised
100 75
25
5050
100
25
75
100
Figure 6. Discrimination and calibration ap-
praisal according to Impact factor of propen-
sity studies. Four were included in the lowest
quartile (with an IF < 2.80), four in the highest
(IF > 6.80), and four with IF between previ-
ous values. Four studies were inserted in not
impacted Journal.
detailed definition of end-points, in the assignment of
events by 2 blinded experienced researchers and in in-
tention to treat analysis.
The same criticism suits statistical analysis because
a low number of events per variable was a common fea-
ture among the screened studies, potentially suggesting
overfitted data and misleading associations.75 Another
tricky finding of the present review is the lack of re-
porting and perhaps conducting of internal control, as
frequently it was not possible to assess calibration or
censoring appraisal.6,74
Finally, omission of the methodological assessment
was not related to quality rating of the journal in which
the paper was published: we found no substantial dif-
ferences among studies stratified according to journal
of publication IF, thus stressing also more careful at-
tention from peer reviewers in studies reporting multi-
variable adjustments.
The main implication of our remarks is a call for re-
searchers to improve the reports about their statistical
analysis with care for internal validation and method-
ological assessment. Our score may be useful to fulfill
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Discrimination Calibration Balance
7 studies 
in the highest 
IF quartile
4 studies 
in the medium
IF quartile
5 studies 
in the lowest
IF quartile
Not appraised
Appraised
40
60
20
80 100
40
60
15
75
15
75 71
29
100
40
60
Figure 7. Discrimination, calibration and
balance appraisal according to Impact fac-
tor of propensity studies with matching. Five
were included in the lowest quartile (with an
IF < 5.24), seven in the highest (IF > 14.82)
and four with IF between previous values.
One study was inserted in not impacted
Journal.
Discrimination Calibration Balance
High
quality
study (n=8)
Moderate
quality
study (n=9)
Not appraised
Appraised
0,38
0,62
0,13
0,87
0,50,5
0,44
0,56
0,11
0,89
0,33
0,67
Figure 8. Discrimination, calibration, and
balance appraisal according to propensity
score with matching studies’ quality.
this aim, helping investigators and reviewers to guide
and correct themselves.
Possible limitation of the present investigation is
the variety of involved studies that broadly differ in
the number of patients included, follow-up length, and
year of publication. Anyway, we consider these limi-
tations avenues for further research because it would
be interesting to evaluate the methodological quality of
medical research in relation to study dimensions and
the period of realization.
In summary, multivariate analysis is spreading
around in medical literature, and as a useful tool to
exploit observational data it needs a more detailed in-
ternal control. For readers, clinicians, and researchers
a simple assessment of methodology is fundamental to
drive critical and conscious employment of scientific
information.
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